Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

被引：19

作者：

Pegoraro, Francesco ^{[1
]}

Maniscalco, Valerio ^{[1
]}

Peyronel, Francesco ^{[2
]}

Westenend, Pieter J. ^{[3
]}

Hendriksz, Tadek R. ^{[4
]}

Roperto, Rosa M. ^{[5
]}

Palumbo, Alessandro A. ^{[6
]}

Sieni, Elena ^{[7
]}

Romagnani, Paola ^{[5
,8
]}

van Bommel, Eric F. H. ^{[9
]}

Vaglio, Augusto ^{[5
,8
]}

机构：

[1] Univ Firenze, Dept Hlth Sci, Florence, Italy

[2] Univ Hosp, Nephrol Unit, Parma, Italy

[3] Albert Schweitzer Hosp, Dutch Natl Ctr Expertise Retroperitoneal Fibrosis, Dept Pathol, Dordrecht, Netherlands

[4] Albert Schweitzer Hosp, Dutch Natl Ctr Expertise Retroperitoneal Fibrosis, Dept Radiol, Dordrecht, Netherlands

[5] Meyer Childrens Hosp, Nephrol & Dialysis Unit, Florence, Italy

[6] Univ Hosp, Dept Radiol, Parma, Italy

[7] Meyer Childrens Hosp, Dept Pediat Hematol & Oncol, Florence, Italy

[8] Univ Firenze, Dept Biomed Expt & Clin Sci Mario Serio, Viale Pieraccini 6, I-50139 Florence, Italy

[9] Albert Schweitzer Hosp, Dept Nephrol, Dutch Natl Ctr Expertise Retroperitoneal Fibrosis, Dordrecht, Netherlands

来源：

BLOOD | 2020年 / 135卷 / 22期

关键词：

LANGERHANS CELL HISTIOCYTOSIS; VEMURAFENIB; NEOPLASMS; EFFICACY; CRITERIA; RECIST;

D O I：

10.1182/blood.2019004478

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1994 / 1997

页数：4

共 50 条

[21] Advances in potential targeted therapies for Erdheim-Chester disease
Cavalli, Giulio
De Luca, Giacomo
Dagna, Lorenzo
EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (03): : 253 - 260
[22] BRAF Mutations in Erdheim-Chester Disease
Campochiaro, Corrado
Dagna, Lorenzo
DERMATOLOGIC CLINICS, 2016, 34 (01) : XI - XII
[23] Sirolimus monotherapy for Erdheim-Chester disease
van Bommel, Eric F. H.
van der Zijden, Mark A.
Gregoor, Peter J. H. Smak
Hendriksz, Tadek R.
Ho-Han, Shiuw H.
Westenend, Pieter J.
ACTA ONCOLOGICA, 2019, 58 (06) : 901 - 905
[24] The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease
Dai, Jia-wen
Lin, He
Chang, Long
Li, Jian
Zhou, Dao-bin
Cao, Xin-xin
ANNALS OF HEMATOLOGY, 2023, 102 (12) : 3335 - 3343
[25] Strategies and treatment alternatives in the management of Erdheim-Chester disease
Mazor, Roei David
Manevich-Mazor, Mirra
Shoenfeld, Yehuda
EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (11): : 891 - 899
[26] The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm
Haroche, Julien
Cohen-Aubart, Fleur
Charlotte, Frederic
Maksud, Philippe
Grenier, Philippe A.
Cluzel, Philippe
Mathian, Alexis
Emile, Jean-Francois
Amoura, Zahir
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (09) : 1033 - 1042
[27] Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia
Haroche, Julien
Papo, Matthias
Cohen-Aubart, Fleur
Charlotte, Frederic
Maksud, Philippe
Grenier, Philippe A.
Cluzel, Philippe
Mathian, Alexis
Emile, Jean-Francois
Amoura, Zahir
PRESSE MEDICALE, 2017, 46 (01): : 96 - 106
[28] Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances
Haroun, Faysal
Millado, Kristen
Tabbara, Imad
ANTICANCER RESEARCH, 2017, 37 (06) : 2777 - 2783
[29] Advances in Understanding and Management of Erdheim-Chester Disease
Kulkarni, Aniruddha Murahar
Gayam, Prasanna Kumar Reddy
Aranjani, Jesil Mathew
LIFE SCIENCES, 2024, 348
[30] Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients
Pegoraro, Francesco
Mazzariol, Martina
Trambusti, Irene
Bakhshi, Sameer
Mallick, Saumyaranjan
Dunkel, Ira J.
van den Bos, Cor
Tezol, Ozlem
Shan, Shijun
Ocak, Suheyla
Giordano, Flavio
De Fusco, Carmela
Gaspari, Stefania
Buccoliero, Anna Maria
Coniglio, Maria Luisa
Buti, Elisa
Romagnani, Paola
Picarsic, Jennifer
Donadieu, Jean
Diamond, Eli L.
Emile, Jean-Francois
Sieni, Elena
Haroche, Julien
Vaglio, Augusto
BLOOD, 2023, 142 (13) : 1167 - 1171

← 1 2 3 4 5 →